MME and hydrops fetalis: Sex‐specificity in patients with HFpEF is also likely supported by the heterogeneity with a possible benefit of sacubitril–valsartan seen in women in the PARAGON‐HF (Prospective Comparison of Angiotensin Receptor–Neprilysin Inhibitor with Angiotensin Receptor Blockers Global Outcomes in HF with Preserved Ejection Fraction) trial.30